The DOI matches its Crossref record.
Mechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine
Abstract
Aminoguanidine-HCl inhibits the formation of advanced glycosylation end products (AGEs) in vitro and in vivo, but the mechanism by which this occurs has not been determined. Aminoguanidine inhibited glucose-derived AGE formation on RNase A by 67–85% at aminoguanidine-glucose molar ratios of 1:5 to 1:50 without affecting the concentration of Amadori products. Fast–atom-bombardment mass spectrometry of RNase peptides incubated with glucose alone or with glucose plus aminoguanidine showed that aminoguanidine inhibited the formation of AGEs without forming an adduct with glycosylated peptide. These data suggest that the primary mechanism of aminoguanidine action is reaction with Amadori-derived fragmentation products in solution. These findings are relevant to the potential clinical use of aminoguanidine in the prevention of diabetic complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
Advanced glycation endproducts—role in pathology of diabetic complications
Ahmed, N. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.09.004 · Cited by 1,455
Advanced protein glycosylation in diabetes and aging
Brownlee, M. D. (1995) · Annual Review of Medicine · doi:10.1146/annurev.med.46.1.223 · Cited by 1,312
Self-citationBASTA, G. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.05.001 · Cited by 999
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Ramasamy, R., Vannucci, S. J., Yan, S. S. D., Herold, K., Yan, S. F., & Schmidt, A. M. (2005) · Glycobiology · doi:10.1093/glycob/cwi053 · Cited by 834
Diabetes and advanced glycation endproducts
Vlassara, H., & Palace, M. R. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.00932.x · Cited by 697
Advanced glycation end products: Key players in skin aging?
Gkogkolou, P., & Böhm, M. (2012) · Dermato-Endocrinology · doi:10.4161/derm.22028 · Cited by 584
Bierhaus, A. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00233-2 · Cited by 555
Platelet activation in type 2 diabetes mellitus
Ferroni, P., Basili, S., Falco, A., & Davì, G. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00836.x · Cited by 493
Aminoguanidine selectively inhibits inducible nitric oxide synthase
Griffiths, M. J. D., Messent, M., MacAllister, R. J., & Evans, T. W. (1993) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1993.tb13907.x · Cited by 397
Limonene: Aroma of innovation in health and disease
Vieira, A. J., Beserra, F. P., Souza, M. C., Totti, B. M., & Rozza, A. L. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.02.007 · Cited by 384
Prevention and Treatment of the Complications of Diabetes Mellitus
Clark, C. M., & Lee, D. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505043321807 · Cited by 369
Matsuoka, T., Kajimoto, Y., Watada, H., Kaneto, H., Kishimoto, M., Umayahara, Y., Fujitani, Y., Kamada, T., Kawamori, R., & Yamasaki, Y. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119126 · Cited by 359
Diabetes and Advanced Glycoxidation End Products
Huebschmann, A. G., Regensteiner, J. G., Vlassara, H., & Reusch, J. E. B. (2006) · Diabetes Care · doi:10.2337/dc05-2096 · Cited by 330
Inhibition of advanced glycation endproduct formation by foodstuffs
Wu, C.-H., Huang, S.-M., Lin, J.-A., & Yen, G.-C. (2011) · Food & Function · doi:10.1039/c1fo10026b · Cited by 328
Potential mechanisms promoting restenosis in diabetic patients
Aronson, D., Bloomgarden, Z., & Rayfield, E. J. (1996) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00496-3 · Cited by 327
Advanced glycation: an important pathological event in diabetic and age related ocular disease
STITT, A. W. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.6.746 · Cited by 306
Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease.
Yang, C. W., Vlassara, H., Peten, E. P., He, C. J., Striker, G. E., & Striker, L. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9436 · Cited by 294
In Vitro Kinetic Studies of Formation of Antigenic Advanced Glycation End Products (AGEs)
Booth, A. A., Khalifah, R. G., Todd, P., & Hudson, B. G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5430 · Cited by 286
Negative consequences of glycation
Brownlee, M. (2000) · Metabolism · doi:10.1016/s0026-0495(00)80078-5 · Cited by 284
Self-citationPharmacological Inhibition of Diabetic Retinopathy
Kern, T. S., & Engerman, R. L. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1636 · Cited by 277
Freedman, B. I., Wuerth, J.-P., Cartwright, K., Bain, R. P., Dippe, S., Hershon, K., Mooradian, A. D., & Spinowitz, B. S. (1999) · Controlled Clinical Trials · doi:10.1016/s0197-2456(99)00024-0 · Cited by 259
Management of coronary artery disease: therapeutic options in patients with diabetes
Hammoud, T., Tanguay, J.-F., & Bourassa, M. G. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00732-4 · Cited by 256
Prevention of Rat Cerebral Aneurysm Formation by Inhibition of Nitric Oxide Synthase
Fukuda, S., Hashimoto, N., Naritomi, H., Nagata, I., Nozaki, K., Kondo, S., Kurino, M., & Kikuchi, H. (2000) · Circulation · doi:10.1161/01.cir.101.21.2532 · Cited by 255
Identification of α-dicarbonyl scavengers for cellular protection against carbonyl stress
Wondrak, G. T., Cervantes-Laurean, D., Roberts, M. J., Qasem, J. G., Kim, M., Jacobson, E. L., & Jacobson, M. K. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00915-7 · Cited by 108
Liu, Y.-W., Zhu, X., Zhang, L., Lu, Q., Wang, J.-Y., Zhang, F., Guo, H., Yin, J.-L., & Yin, X.-X. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.08.029 · Cited by 72
Metadata
- Authors
- Edelstein, D., & Brownlee, M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1992-01-01
- Volume
- 41
- Issue
- 1
- Pages
- 26-29
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2024907296
- Cited by
- 360
- References
- 0
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.